These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25856769)

  • 1. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
    Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
    Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Efken P; Mohl W; Hoffstadt M; Krause T; Schweitzer A; Schnoy E; Atreya R; Teich N; Trentmann L; Ehehalt R; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2024 May; 30(5):746-756. PubMed ID: 37523666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
    Shivashankar R; Pardi DS
    Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.
    Ananthakrishnan AN; Hur C; Korzenik JR
    Dig Dis Sci; 2012 Feb; 57(2):472-80. PubMed ID: 21909990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of natalizumab for multiple sclerosis and Crohn's disease: a meta analysis].
    Li YY; Li YP; Sun X; Wang L; Wen J; Cheng L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):533-42. PubMed ID: 21050557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
    Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
    Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons.
    Miligkos M; Papamichael K; Vande Casteele N; Mantzaris GJ; Gils A; Levesque BG; Zintzaras E
    Clin Ther; 2016 Jun; 38(6):1342-1358.e6. PubMed ID: 27091732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP; Cross RK
    Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.